Literature DB >> 16774952

Antibodies to fibroblasts in idiopathic and scleroderma-associated pulmonary hypertension.

M C Tamby1, M Humbert, P Guilpain, A Servettaz, N Dupin, J J Christner, G Simonneau, J Fermanian, B Weill, L Guillevin, L Mouthon.   

Abstract

The aim of the present study was to investigate the presence of anti-fibroblast antibodies in patients with idiopathic or scleroderma-associated pulmonary arterial hypertension (PAH) and healthy controls. PAH was documented by right-heart catheterisation (mean pulmonary artery pressure at rest >25 mmHg). Serum immunoglobulin (Ig)G and IgM reactivities of patients with idiopathic PAH (n = 35), scleroderma-associated PAH (n = 10), diffuse (n = 10) or limited cutaneous (n = 10) scleroderma without PAH and age- and sex-matched healthy individuals (n = 65) were analysed by cell-based ELISA and immunoblotting on normal human fibroblasts. As assessed by ELISA, 14 out of 35 (40%) patients with idiopathic PAH and three out of 10 (30%) patients with scleroderma-associated PAH expressed anti-fibroblast IgG antibodies. IgG from all individuals bound to one major 40-kDa protein band. IgG from patients with idiopathic PAH bound to two 25- and 60-kDa bands with a higher intensity than IgG from other individuals. In conclusion, immunoglobulin G anti-fibroblast antibodies are present in the serum of patients with pulmonary arterial hypertension. Immunoglobulin G from patients with idiopathic pulmonary arterial hypertension or scleroderma-associated pulmonary arterial hypertension express distinct reactivity profiles with fibroblasts antigens, suggesting distinct target antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16774952     DOI: 10.1183/09031936.06.00152705

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  34 in total

Review 1.  Pulmonary arterial hypertension associated with systemic sclerosis.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Expert Rev Respir Med       Date:  2011-04       Impact factor: 3.772

2.  Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.

Authors:  Amélie Servettaz; Niloufar Kavian; Carole Nicco; Vanessa Deveaux; Christiane Chéreau; Andrew Wang; Andreas Zimmer; Sophie Lotersztajn; Bernard Weill; Frédéric Batteux
Journal:  Am J Pathol       Date:  2010-05-27       Impact factor: 4.307

Review 3.  Functional autoantibodies in systemic sclerosis.

Authors:  Jeannine Günther; Judith Rademacher; Jakob M van Laar; Elise Siegert; Gabriela Riemekasten
Journal:  Semin Immunopathol       Date:  2015-08-21       Impact factor: 9.623

4.  Cytokines, Chemokines, and Inflammation in Pulmonary Arterial Hypertension.

Authors:  Shuxin Liang; Ankit A Desai; Stephen M Black; Haiyang Tang
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 5.  Functional autoantibodies in systemic sclerosis pathogenesis.

Authors:  Angela Kill; Gabriela Riemekasten
Journal:  Curr Rheumatol Rep       Date:  2015-05       Impact factor: 4.592

Review 6.  Cytokines in the immunopathology of systemic sclerosis.

Authors:  Jasmin Raja; Christopher Paul Denton
Journal:  Semin Immunopathol       Date:  2015-07-08       Impact factor: 9.623

7.  T lymphocyte subset abnormalities in the blood and lung in pulmonary arterial hypertension.

Authors:  E D Austin; M T Rock; C A Mosse; C L Vnencak-Jones; S M Yoder; I M Robbins; J E Loyd; B O Meyrick
Journal:  Respir Med       Date:  2009-10-31       Impact factor: 3.415

Review 8.  The right ventricle in scleroderma (2013 Grover Conference Series).

Authors:  Paul M Hassoun
Journal:  Pulm Circ       Date:  2015-03       Impact factor: 3.017

Review 9.  Inflammation and immunity in the pathogenesis of pulmonary arterial hypertension.

Authors:  Marlene Rabinovitch; Christophe Guignabert; Marc Humbert; Mark R Nicolls
Journal:  Circ Res       Date:  2014-06-20       Impact factor: 17.367

Review 10.  Scleroderma lung disease.

Authors:  Joshua J Solomon; Amy L Olson; Aryeh Fischer; Todd Bull; Kevin K Brown; Ganesh Raghu
Journal:  Eur Respir Rev       Date:  2013-03-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.